In line with this finding, a systematic review and meta‐analysis published in 2022 indicated that curcumin therapy had a reducing effect on ALT in patients with NAFLD (Ngu et al., 2022). The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.